Q-omics provides the consensus-scored MIR626 profile across patient tissues and cancer cell-line models. MIR626 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR626 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR626 RNA expression shows 7,144 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight THCA, BRCA, and LAML as cancer lineages where MIR626 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR626 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR626 survival associations across molecular data types. MIR626 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR626 RNA expression–survival associations across cancer types. High MIR626 expression shows unfavorable associations in THCA, BRCA, MESO, LIHC and OV, but favorable associations in HNSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR626 RNA expression.
This table summarizes MIR626 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR626. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR626 shows higher tumor expression in BRCA. The BRCA box plot shows higher MIR626 RNA expression in tumor versus normal tissue (log2 FC = +0.173, t-test p = .030).
This table shows molecular features associated with MIR626 in patient tissues and cancer cell lines. In patient samples, MIR626 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
